Purinoceptor P2Y12 antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Purinoceptor P2Y12 antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Purinoceptor P2Y12 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Purinoceptor P2Y12 antagonists: Overview
The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses. Defects of P2Y12R should be suspected when ADP, even at high concentrations (? 10 ?m), is unable to induce full, irreversible platelet aggregation. P2Y12R also plays a role in inflammation: its role in the pathogenesis of allergic asthma has been well characterized. In addition, inhibition or genetic deficiency of P2Y12R has antitumor effects. Drugs inhibiting P2Y12R are potent antithrombotic drugs.
Report Highlights
This segment of the Purinoceptor P2Y12 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Purinoceptor P2Y12 antagonists Emerging Drugs
Further product details are provided in the report……..
Purinoceptor P2Y12 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Purinoceptor P2Y12 antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Purinoceptor P2Y12 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Purinoceptor P2Y12 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinoceptor P2Y12 antagonists drugs.
Purinoceptor P2Y12 antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Purinoceptor P2Y12 antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Purinoceptor P2Y12 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Purinoceptor P2Y12 antagonists: Overview
The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses. Defects of P2Y12R should be suspected when ADP, even at high concentrations (? 10 ?m), is unable to induce full, irreversible platelet aggregation. P2Y12R also plays a role in inflammation: its role in the pathogenesis of allergic asthma has been well characterized. In addition, inhibition or genetic deficiency of P2Y12R has antitumor effects. Drugs inhibiting P2Y12R are potent antithrombotic drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Purinoceptor P2Y12 antagonists R&D. The therapies under development are focused on novel approaches for Purinoceptor P2Y12 antagonists.
This segment of the Purinoceptor P2Y12 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Purinoceptor P2Y12 antagonists Emerging Drugs
- Prasugrel: Daiichi Sankyo
- Ticagrelor: AstraZeneca
Further product details are provided in the report……..
Purinoceptor P2Y12 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Purinoceptor P2Y12 antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Purinoceptor P2Y12 antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Purinoceptor P2Y12 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Purinoceptor P2Y12 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinoceptor P2Y12 antagonists drugs.
Purinoceptor P2Y12 antagonists Report Insights
- Purinoceptor P2Y12 antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Purinoceptor P2Y12 antagonists drugs?
- How many Purinoceptor P2Y12 antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Purinoceptor P2Y12 antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Purinoceptor P2Y12 antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Purinoceptor P2Y12 antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daiichi Sankyo
- AstraZeneca
- Idorsia Pharmaceuticals
- Synokem Pharmaceuticals
- GLSynthesis
- Prasugrel
- Ticagrelor
- Selatogrel
- Ticagrelor SR
- GLS-409
Introduction
Executive Summary
Purinoceptor P2Y12 antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Purinoceptor P2Y12 antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Selatogrel: Idorsia Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
GLS 409: GLSynthesis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Purinoceptor P2Y12 antagonists Key Companies
Purinoceptor P2Y12 antagonists Key Products
Purinoceptor P2Y12 antagonists- Unmet Needs
Purinoceptor P2Y12 antagonists- Market Drivers and Barriers
Purinoceptor P2Y12 antagonists- Future Perspectives and Conclusion
Purinoceptor P2Y12 antagonists Analyst Views
Purinoceptor P2Y12 antagonists Key Companies
Appendix
Executive Summary
Purinoceptor P2Y12 antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Purinoceptor P2Y12 antagonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Selatogrel: Idorsia Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
GLS 409: GLSynthesis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Purinoceptor P2Y12 antagonists Key Companies
Purinoceptor P2Y12 antagonists Key Products
Purinoceptor P2Y12 antagonists- Unmet Needs
Purinoceptor P2Y12 antagonists- Market Drivers and Barriers
Purinoceptor P2Y12 antagonists- Future Perspectives and Conclusion
Purinoceptor P2Y12 antagonists Analyst Views
Purinoceptor P2Y12 antagonists Key Companies
Appendix